Sudhin Biopharma Co.
Developing the most efficient continuous bioprocessing platform technologies
Oct 17th, 2017
Dhinakar Kompala presents an invited talk on "Novel compact cell settler for high cell density perfusion bioreactor cultures of microbial (and mammalian) cells" at the BioProduction Congress in Convention Centre Dublin, Ireland.
Aug 2017
Sudhin Biopharma Co. publishes its first peer-reviewed article: Freeman, Cassandra A., Premsingh S.D. Samuel, and Dhinakar S. Kompala, "Compact cell settlers for perfusion cultures of microbial (and mammalian) cells", in a special issue of Biotechnology Progress 33:913-922 (2017). DOI 10.1002/btpr.2533
May 4th, 2017
Dhinakar Kompala presents a 2 minute introduction to Sudhin’s innovation at Small and Medium Enterprises Innovation Showcase during the Launch or Kickoff National Meeting of the newly funded National Institute for Innovation in Manufacturing Biopharmaceutics, of which Sudhin Biopharma just joined as a SME member.
Feb 15th, 2017
Second beta testing of our Stainless Steel Compact Cell Settler has commenced at a large biopharmaceutical company in Sweden. More devices are available for beta testing by other interested companies.
Dec 1st, 2016

Inclined Settlers

Sudhin Biopharma Company has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I grant for $225,000 to conduct research and development (R&D) work on demonstrating the power of our compact cell settler to achieve high cell densities and productivities in continuous perfusion bioreactor cultures of recombinant mammalian cells.

With this new grant funding, we plan to culture (i) recombinant Chinese hamster ovary cells and (ii) murine hybridoma cells in continuous perfusion bioreactors attached with our 4" or 6" compact cell settler and demonstrate that dead cells and cell debris can be removed selectively via the settler top effluent while the live and productive cells are recycled continuously to the bioreactor. Our patent-pending compact cell settler technology is a more efficiently scaled version (with much smaller footprint and higher settling capacity) of the proven "inclined settler" technology, which has been used successfully in commercial production of some therapeutic biologics. We expect to reproduce for the mammalian cell cultures our recently obtained excellent results for the smaller and hence more challenging yeast Pichia pastoris cells, demonstrating very high cell densities and productivities in continuous perfusion bioreactor for over two months without any membrane clogging or protein sieving challenges seen with other cell retention devices.

"The National Science Foundation supports small businesses with the most innovative, cutting-edge ideas that have the potential to become great commercial successes and make huge societal impacts," said Barry Johnson, Director of the NSF’s Division of Industrial Innovation and Partnerships. "We hope that this seed funding will spark solutions to some of the most important challenges of our time across all areas of science and technology."

Oct 15th, 2016
Beta testing of our Novel Compact Cell Settler has commenced at a large biopharmaceutical company in USA. More devices are available for beta testing by other interested companies.
Jun 8th, 2016
Dhinakar Kompala discusses his opinions about the advantages of continuous perfusion bioreactor culture over fed-batch bioreactor culture in a brief interview with a contract manufacturing company Patheon at the BIO International Convention in San Francisco, CA.

May 9th, 2016
Dhinakar presents the latest results from the novel compact cell settlers to achieve very high cell densities of yeast Pichia pastoris cells secreting a recombinant protein, pro-glargine, an insulin analog continuously harvested from a 5 liter perfusion bioreactor.

Feb 11th, 2016
Sudhin Biopharma Co. receives an Early Stage Capital and Retention grant of $50,000 from State of Colorado Office of Economic Development and International Trade. This is the first installment out of a total grant of $250,000 over three years, providing matching funds to other funding sources, including contracts, grants and investments.

Dec 19th, 2015:
Dhinakar presents an invited talk on “Novel Compact Cell Settlers for Perfusion Cultures of (Microbial and Mammalian) cells” at the Bioprocessing India 2015 conference at Indian Institute of Technology, Madras. See below for the slides.

Also presented as a poster paper at the ECI conference on “Integrated Continuous Bioprocessing” in Berkeley, CA on Nov 3rd, 2015.

Dec 10th, 2015:
Sudhin Biopharma Co. receives a Phase IB supplemental funding of $29,999 to the Small Business Innovative Research (SBIR) Phase I grant from the US National Science Foundation.

Sep 1st, 2015
Dr. Niles Utlaut, M.D., an angel investor, joins our newly constituted Board of Directors, along with our first angel investor, Dr. Sushila Kompala, M.D.

Mr. Khishore Pridhivi, MBA, joins the Board of Directors of our majority-owned subsidiary company in India, Sudhin Biotech Private Limited, along with Mr. Srinagesh Talatam, MBA.

Founder and CEO, Dr. Dhinakar Kompala, Ph.D. serves as the Chairman of both these Boards.

Jul 1st, 2015
Sudhin Biopharma Co. receives a Small Business Innovative Research (SBIR) Phase I grant of $150,000 from the US National Science Foundation.

Apr 21st, 2015
Dhinakar S Kompala presents at American Chemical Society's Entrepreneur Showcase West in San Diego, CA.